Delving into the Latest Updates on Bis(allixinato)oxovanadium(IV) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Complex 3(Wakunaga Pharmaceutical)

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesEndocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 1

Inactive Indication-

Originator Organization

Wakunaga Pharmaceutical Co., Ltd.

Active Organization

Wakunaga Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC24H34O9V

InChIKeyAPQIEAOGIMPNDC-UHFFFAOYSA-L

CAS Registry897028-47-6

Activating multiple anti-cancer pathways has great potential for tumor treatment. Herein, we synthesized two binuclear Cu(II) hydrazone complexes ([Cu₂(HL1)₂Cl₂] 1 and [Cu₂(HL1)₂Br₂] 2) and two mononuclear hydrazone-Cu(II) complexes ([Cu(HL2)Cl]·CH₃OH 3 and [Cu(HL2)(H₂O)Br]·2H₂O 4), to evaluate their anti-lung cancer activities. MTT assays revealed that the Cu(II) complexes demonstrate superior anticancer activity compared to cisplatin. Among them, complex 3 exhibited selective toxicity towards A549 cancer cells in comparison to normal cells and demonstrated hemolytic activity comparable to cisplatin. The low toxicity and effective antitumor capabilities of complex 3 have been confirmed in xenograft experiments using A549 tumor-bearing mice. Interestingly, complex 3 eradicates lung tumor cells both in vivo and in vitro by initiating multiple anticancer pathways, including cuproptosis. Our research extends the study of hydrazone copper complexes and provides strategies for the treatment of lung cancer.

100 Deals associated with Bis(allixinato)oxovanadium(IV)

Login to view more data